Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The HOPE4MCI Trial

Time: 9:30 am
day: Day One


  • Novel therapeutic targets; hippocampal overactivity driving Alzheimer’s Disease pathology (amyloid deposition, tau progression and cortical atrophy) in patients with amnestic mild cognitive impairment
  • Success Story: AGB101 (low dose levetiracetam) reduces hippocampal overactivity and restores task related episodic memory function in a Phase 2A study in patients with amnestic mild cognitive impairment
  • Clinical Update: HOPE4MCI is a fully enrolled Phase 2B study investigating the effects of AGB101 in patients with mild cognitive impairment due to Alzheimer’s Disease
  • Precision medicine approach to patient selection; strict memory cutoff leads to amyloid positivity which ensures hippocampal overactivity and disease progression
  • Utilization of imaging data (MK-6240 tau PET scans and structural MRI) coupled with the use of blood samples a resource for understanding AD biomarkers and clinical trial outcomes